AugustoEVillegasMD

Breast Cancer, Hematologic Oncology, Thoracic Cancer

Physician

Dr. Villegas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
4689 US Highway 17 Ste 25
Fleming Island, FL 32003
Phone+1 904-269-6526

Fax+1 904-269-6527

University of Florida College of Medicine JacksonvilleFellowship, Hematology and Medical Oncology, 2003 - 2005
Damas HospitalResidency, Internal Medicine, 1996 - 1999
Ponce Health Sciences University School of MedicineClass of 1996

PubMed

30 citations
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
Corinne Faivre-Finn, David R. Spigel, Suresh Senan, Corey J. Langer, Bradford A. Perez
Lung Cancer. 2021-01-01
289 citations
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
Jhanelle E. Gray, A. Villegas, Davey B. Daniel, David Vicente, Shuji Murakami
Journal of Thoracic Oncology. 2020-02-01
24 citations
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
Mark A. Socinski, Mustafa Ozguroglu, A. Villegas, Davey B. Daniel, David Vicente
Clinical Lung Cancer. 2021-06-12

Journal Articles

Overall Survival with Durvalumab After Chemoradiotherapy in Stage III NSCLC
David R Spigel, Davey Daniel, Jhanelle E Gray, Augusto Villegas, Tarek Mekhail, Alberto Chiappori, The New England Journal of Medicine
Trastuzumab Emtansine (T-dM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety and Biomarkers
Augusto Villegas, Christina S Baik, Clinical Cancer Research